Literature DB >> 33243988

A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia.

Kyle Spinler1,2, Jeevisha Bajaj1,2, Takahiro Ito1,2, Bryan Zimdahl1,2,3, Michael Hamilton1,2, Armin Ahmadi1,2, Claire S Koechlein1,2, Nikki Lytle1,2, Hyog Young Kwon1,2, Ferdous Anower-E-Khuda4, Hao Sun5, Allen Blevins1,2, Joi Weeks1,2, Marcie Kritzik1,2, Jan Karlseder6, Mark H Ginsberg5, Pyong Woo Park7, Jeffrey D Esko4, Tannishtha Reya8,9,10,11.   

Abstract

Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason for treatment failure and relapse. Thus, identifying the cells responsible for residual disease and leukemia re-growth is critical to better understanding how they are regulated. Here, we show that a knock-in reporter mouse for the stem cell gene Musashi 2 (Msi2) allows identification of leukemia stem cells in aggressive myeloid malignancies, and provides a strategy for defining their core dependencies. Specifically, we carry out a high throughput screen using Msi2-reporter blast crisis chronic myeloid leukemia (bcCML) and identify several adhesion molecules that are preferentially expressed in therapy resistant bcCML cells and play a key role in bcCML. In particular, we focus on syndecan-1, whose deletion triggers defects in bcCML growth and propagation and markedly improves survival of transplanted mice. Further, live imaging reveals that the spatiotemporal dynamics of leukemia cells are critically dependent on syndecan signaling, as loss of this signal impairs their localization, migration and dissemination to distant sites. Finally, at a molecular level, syndecan loss directly impairs integrin β7 function, suggesting that syndecan exerts its influence, at least in part, by coordinating integrin activity in bcCML. These data present a platform for delineating the biological underpinnings of leukemia stem cell function, and highlight the Sdc1-Itgβ7 signaling axis as a key regulatory control point for bcCML growth and dissemination.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33243988      PMCID: PMC7691523          DOI: 10.1038/s41467-020-19782-x

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  69 in total

1.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

4.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

5.  A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.

Authors:  Muhammad Yassin; Nasma Aqaqe; Abed Alkader Yassin; Peter van Galen; Eitan Kugler; Bradley E Bernstein; Maya Koren-Michowitz; Jonathan Canaani; Arnon Nagler; Eric R Lechman; John E Dick; Erno Wienholds; Shai Izraeli; Michael Milyavsky
Journal:  Leukemia       Date:  2019-01-31       Impact factor: 11.528

6.  Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

Authors:  Sabine Mumprecht; Christian Schürch; Juerg Schwaller; Max Solenthaler; Adrian F Ochsenbein
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

7.  Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.

Authors:  Hyog Young Kwon; Jeevisha Bajaj; Takahiro Ito; Allen Blevins; Takaaki Konuma; Joi Weeks; Nikki K Lytle; Claire S Koechlein; David Rizzieri; Charles Chuah; Vivian G Oehler; Roman Sasik; Gary Hardiman; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2015-07-23       Impact factor: 24.633

8.  Association of reactive oxygen species levels and radioresistance in cancer stem cells.

Authors:  Maximilian Diehn; Robert W Cho; Neethan A Lobo; Tomer Kalisky; Mary Jo Dorie; Angela N Kulp; Dalong Qian; Jessica S Lam; Laurie E Ailles; Manzhi Wong; Benzion Joshua; Michael J Kaplan; Irene Wapnir; Frederick M Dirbas; George Somlo; Carlos Garberoglio; Benjamin Paz; Jeannie Shen; Sean K Lau; Stephen R Quake; J Martin Brown; Irving L Weissman; Michael F Clarke
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential.

Authors:  J Domen; S H Cheshier; I L Weissman
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  2 in total

1.  Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer.

Authors:  Nan Wang; Yuanting Gu; Lin Li; Jiangrui Chi; Xinwei Liu; Youyi Xiong; Chaochao Zhong
Journal:  J Inflamm Res       Date:  2022-06-14

Review 2.  The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.

Authors:  L Paige Ferguson; Emily Diaz; Tannishtha Reya
Journal:  Trends Cancer       Date:  2021-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.